Ann: OmniCAR technical issues resolved and program to progress, page-31

Whoaw.... that's a lot to take in! What has me miffed, though, is the fact that OmniCAR was always spruiked as being controllable - accommodating not only both sequential and simultaneous arming but also down-regulating the targeting ligand activity... akin to switching it off. But it was only highlighted that there was an issue when the results of our collab with Thermo Fisher were presented by Bec in the TF webinar. I thought it must have been somehow related to the choice of cell-engineering... the non-viral transduction method (cheaper for commercial scaling). Since then, and only recently too, the technical issues were expressed as being associated with "tonic signalling" which is along the lines (sort of) what your investigation via ChatGPT shows. I'll see if I can find the original Chatty research gave me on that specific subject.

Whatever research that PTX has carried out in collab with Peter Mac and CSIRO certainly sounds worthwhile and certainly an achievement. Perhaps it was always known that OmniCAR required far more extensive pre-clinical development than promoted prior to the TF collab (excuse my cynicism but whilst it promised the earth... maybe only now it might). Its a bit like CellPryme being "clinic ready"... pfffttt... well two and half years later, it actually sounds like it is ready for the clinic. Anyway, I will leave it that.